Netflix topped Wall Street expectations in the second quarter, boosted by strong subscriber growth, rising ad revenue, and hit content.

Hims & Hers Health (HIMS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Axios Visuals SPACs are reaching heights not seen since 2021, despite their reputation as a symptom of an overly frothy market. Driving the news: 74 blank check companies have gone public via deSPAC ...

The overall sentiment of these big-money traders is split between 31% bullish and 50%, bearish. Out of all of the special options we uncovered, 3 are puts, for a total amount of $106,898, and 13 are ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The ...

Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

An article in The Journal For Nurse Practitioners found that Depo-Testosterone was the most cost-efficient TRT option, and ...

Hims reports that many men avoid doctor visits, worsening health. Erectile dysfunction (ED) can be a sign of serious issues, ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

Amazon's cloud arm, AWS, has slashed at least hundreds of jobs—including roles in specialist, training, certification, and ...